Vanda Pharmaceuticals (VNDA) Stock Soars After FDA Greenlights Bysanti for Schizophrenia and Bipolar

Posted on by

TLDR

  • The FDA greenlit Vanda Pharmaceuticals’ Bysanti (milsaperidone) for schizophrenia and acute bipolar I disorder.
  • Following the announcement, Vanda’s stock soared by roughly 44% in after-hours trading.
  • Once in the body, milsaperidone transforms into iloperidone, making it chemically akin to Vanda’s existing drug, Fanapt.
  • Vanda intends to roll out Bysanti in the U.S. during Q3 2026, with a phase 3 trial for major depressive disorder currently underway.
  • Despite the stock jump, Vanda has financial red flags, such as a negative operating margin and a low Altman Z-Score.

Vanda Pharmaceuticals scored a major win on Friday. The U.S. FDA approved its new antipsychotic drug, Bysanti, for treating schizophrenia and acute bipolar I disorder.

VNDA Stock Card

The market reacted quickly. VNDA stock jumped by roughly 44% in after-hours trading after the news.

Bysanti’s generic name is milsaperidone. It falls into the atypical antipsychotic drug category, which works by blocking dopamine and serotonin receptors in the brain.

Here’s where it gets interesting. Once absorbed by the body, milsaperidone converts to iloperidone — and iloperidone is the active ingredient in Vanda’s already-approved drug, Fanapt.

In other words, the two drugs end up producing similar drug levels in the patient. Vanda states that Bysanti has a safety profile comparable to Fanapt.

Vanda plans to launch Bysanti in the U.S. during Q3 2026. The company is also conducting a phase 3 trial testing Bysanti as a once-daily add-on treatment for major depressive disorder, with results expected later this year.

Questions About Market Fit

Not everyone is confident that Bysanti will carve out a significant market share.

Jefferies analyst Andrew Tsai noted before the approval that Bysanti is “essentially much the same drug with similar efficacy and safety” as Fanapt. He questioned why patients would choose Bysanti, especially if Fanapt goes generic around late 2027 or 2028.

Tsai projects Bysanti could reach around $200 million in sales by 2033.

Competitors in the antipsychotic market include Bristol-Myers Squibb’s Cobenfy and Johnson & Johnson’s Caplyta, both approved for schizophrenia and bipolar disorder.

Financial Health Worth Watching

The stock surge is eye-catching, but Vanda’s financials tell a more cautious story.

Revenue stood at $216.11 million, but the company’s 3-year revenue growth rate was -6.3%. The operating margin is -69.95%, and the net margin is -102.02%.

Vanda does exhibit a strong gross margin of 93.96%, which reflects solid product-level profitability before operating costs are factored in.

On the balance sheet, the current ratio is 2.39 and the debt-to-equity ratio is low at 0.04, indicating manageable short-term obligations. However, an Altman Z-Score of 0.21 places the company in the financial distress zone, and a Piotroski F-Score of 3 indicates weak business operations.

Institutional investors hold approximately 76% of the stock. The analyst consensus target price is $13.63, suggesting potential for growth from pre-announcement levels.

The 14-day RSI was 35.52 before the approval news, indicating the stock had been nearing oversold territory.

Vanda’s market cap was approximately $340.46 million before the after-hours surge.

The company’s existing portfolio includes HETLIOZ for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome, in addition to Fanapt.